TYRA trades 78.3% below Wall Street's consensus target of $50.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TYRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Tyra Biosciences, Inc. (TYRA) has a Wall Street consensus price target of $50.50, based on estimates from 7 covering analysts. With the stock currently trading at $28.32, this represents a potential upside of +78.3%. The company has a market capitalization of $1.68B.
Analyst price targets range from a low of $42.00 to a high of $59.00, representing a 34% spread in expectations. The median target of $51.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TYRA trades at a trailing P/E of -14.1x. Analysts expect EPS to grow -22.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
KROSKeros Therapeutics, Inc. | $341M | $10.65 | $102.60 | +863.4% | Buy | — | 16 |
NUVLNuvalent, Inc. | $9.1B | $123.43 | $132.74 | +7.5% | Hold | — | 18 |
PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
MRUSMerus N.V. | $6.8B | $90.00 | $88.69 | -1.5% | Hold | — | 22 |
ERASErasca, Inc. | $4.3B | $13.67 | $17.50 | +28.0% | Buy | — | 11 |
RGENRepligen Corporation | $7.4B | $132.02 | $158.67 | +20.2% | Buy | 65.9x | 24 |
ICLRICON Public Limited Company | $11.2B | $146.00 | $139.90 | -4.2% | Buy | 13.8x | 30 |
CRLCharles River Laboratories International, Inc. | $8.9B | $185.00 | $214.14 | +15.8% | Buy | 16.7x | 37 |
MEDPMedpace Holdings, Inc. | $13.1B | $460.20 | $498.86 | +8.4% | Hold | 27.1x | 19 |
ARVNArvinas, Inc. | $495M | $7.67 | $14.75 | +92.3% | Buy | — | 26 |
Quick answers to the most common questions about buying TYRA stock.
The consensus Wall Street price target for TYRA is $50.5, representing 78.3% upside from the current price of $28.32. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TYRA has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $50.5 implies 78.3% upside from current levels.
TYRA's current price is $28.32 with a consensus target of $50.5 (78.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $59 for TYRA, while the most conservative target is $42. The consensus of $50.5 represents the median expectation. These targets typically reflect 12-month expectations.
TYRA is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TYRA stock forecast based on 7 Wall Street analysts shows a consensus price target of $50.5, with estimates ranging from $42 (bear case) to $59 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TYRA, with a "Buy" consensus rating and $50.5 price target (78.3% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TYRA analyst price targets range from $42 to $59, a 34% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.